Serum albumin changes and multivariate dynamic risk modelling in chronic heart failure

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 437-443

  Jabbour, Richard ^a   Ling, Hua Zen ^b   Norrington, Karl ^a   Amaral, Nelson ^a   Zaman, Nabeela ^a   Aggarwal, Suneil ^b   Aung, Nay ^b   Barron, Anthony ^a   Manisty, Charlotte ^a   Baruah, Resham ^b   Cole, Graham D ^a   Missouris, Constantinos G ^c   Mayet, Jamil ^a   Francis, Darrel P ^a   Cheng, Adrian S ^d   Thomas, Martin ^b   Woldman, Simon ^b   Okonko, Darlington O ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c WEXHAM PARK HOSPITAL   (United Kingdom)

^d KETTERING GENERAL HOSPITAL   (United Kingdom)

Author keywords

Albumin; Heart failure; Prognosis

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; HEMOGLOBIN; BIOLOGICAL MARKER; SERUM ALBUMIN;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CENTRAL VENOUS PRESSURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE DYNAMIC RISK MODELING; PROGNOSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL RATE; SYSTOLIC HEART FAILURE; VALIDATION PROCESS; BLOOD; CHRONIC DISEASE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CHRONIC DISEASE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE;

EID: 84922399182     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.096     Document Type: Article

References (26)

1. Aaronson KD, Cowger J. Heart failure prognostic models. Why bother? Circ Heart Fail 2012; 5: 6-9.
2. Zafrir B, Goren Y, Paz H, et al. Risk score model for predicting mortality in advanced heart failure patients followed in a heart failure clinic. Congest Heart Fail 2012; 18: 254-61.
3. Frey A, Kroiss M, Berliner D, et al. Prognostic impact of subclinical thyroid dysfunction in heart failure. Int J Cardiol 2013; 168(1): 300-5.
4. Ketchum ES, Levy WC. Establishing prognosis in heart failure: A multimarker approach. Prog Cardiovasc Dis 2011; 54: 86-96.
5. Anand IS, Kuskowski MA, Rector TS, et al. Anemia and change in haemoglobin over time related to mortality and morbidity in patients with chronic heart failure. Results from Val-HeFT. Circulation 2005; 112: 1121-7.
6. Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail 2011; 13: 1161-71.
7. Adlbrecht C, Kommata S, Hülsmann M, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008; 29: 2343-50.
8. Zamora E, Lupón J, Vila J, et al. Estimated glomerular filtration rate and prognosis in heart failure: Value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and cockroft-gault formulas. J Am Coll Cardiol 2012; 59: 1709-15.
9. Lourenço BH, Vieira LP,Macedo A, Nakasato M,MarucciMde F, Bocchi EA. Nutritional status and adequacy of energy and nutrient intakes among heart failure patients. Arq Bras Cardiol 2009; 93: 541-8.
10. Herzer K, Kneiseler G, Bechmann LP, et al. Onset of heart failure determines the hepatic cell death pattern. Ann Hepatol 2011; 10: 174-9.
11. Arques S,Ambrosi P. Human serum albumin in the clinical syndrome of heart failure. J Card Fail 2011; 17: 451-8.
12. da PL Luz, Shubin H, Weil MH, Jacobson E, Stein L. Pulmonary edema related to changes in colloid osmotic and pulmonary artery wedge pressure in patients after acute myocardial infarction. Circulation 1975; 51: 350e7.
13. Gaar Jr KA, Taylor AE, Owens LJ, Guyton AC. Effect of capillary pressure and plasma protein on development of pulmonary edema. Am J Physiol 1967; 213: 79e82.
14. Eising GP, Niemeyer M, Gunther T, et al. Does a hyperoncotic cardiopulmonary bypass prime affect extravascular lungwater and cardiopulmonary function in patients undergoing coronary artery bypass surgery? Eur J Cardiothorac Surg 2001; 20: 282e9.
15. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. Am Heart J 2008; 155: 883-9.
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J 2008; 29: 2388-442.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. For themodification of diet in renal disease study group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-70.
18. Arques S, Roux E, Sbragia P, Gelisse R, Pieri B, Ambrosi P. Usefulness of serum albumin concentration for in-hospital risk stratification in frail, elderly patients with acute heart failure. Insights from a prospective, monocenter study. Int J Cardiol 2008; 125: 265-7.
19. Liu M, Chan CP, Yan BP, et al. Albumin levels predict survival in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2012; 14: 39-44.
20. Phillips A, Shaper AG,Whincup PH. Association between serum albumin andmortality from cardiovascular disease, cancer, and other causes. Lancet Dec 16 1989; 2(8677): 1434-6.
21. Gopal DM, Kalogeropoulos AP, Georgiopoulou VV, et al. Serum albumin concentration and heart failure risk: The Health, Aging, and Body Composition Study. Am Heart J 2010; 160: 279-85.
22. Allen LA, Felker GM, Pocock S, et al. CHARM investigators. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009; 11: 170e7.
23. Schalk BWM, Visser M, Bremmer MA, Penninx BW, Boulter LM, Deeg DJ. Change of serum albumin and risk of cardiovascular disease and all-cause mortality: Longitudinal Aging Study Amsterdam. Am J Epidemiol 2006; 164: 969-77.
24. Ambrosy AP, Vaduganathan M, Huffman MD, et al. EVEREST trial investigators. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. Eur J Heart Fail 2012; 14: 302-11.
25. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisitingmortality predictability of serum albumin in the dialysis population: Time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant 2005; 20: 1880-8.
26. Su W, An T, Zhou Q, et al. Serum albumin is a useful prognostic indicator and adds important information to NT-proBNP in a Chinese cohort of heart failure. Clin Biochem 2012; 45: 561-5.